Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.

about

Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine

P2860

Q57106381-07202FED-9588-46CB-A8A7-8E129C5E875C Q57107703-AEFD0086-B819-447F-926C-D3F4D03ADACD

P2860

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.

Item

http://www.wikidata.org/entity/Q50034009

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.

@en

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.

@nl

type

Item

label

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.

@en

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.

@nl

prefLabel

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.

@en

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.

@nl

P1476

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.

@en

P2093

Danielle Meyrick

http://www.w3.org/2001/XMLSchema#string

J Harvey Turner

http://www.w3.org/2001/XMLSchema#string

Nat P Lenzo

http://www.w3.org/2001/XMLSchema#string

P2860

Screening for prostate cancer

The current and future role of magnetic resonance imaging in prostate cancer detection and management

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status

Epidermal growth factor receptor inhibitors: coming of age

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Radiolabeling of DOTA-like conjugated peptides with generator-produced (68)Ga and using NaCl-based cationic elution method.

[(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.

Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

P31

scholarly article

P356

10.3390/DIAGNOSTICS8010016

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29439481

http://www.w3.org/2001/XMLSchema#string

P932

5871999

http://www.w3.org/2001/XMLSchema#string

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.

about

P2860

P2860

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P577

P698

P932